153 related articles for article (PubMed ID: 19184003)
1. CD4+ T cell responses to HLA-DP5-restricted wild-type sequence p53 peptides in patients with head and neck cancer.
Chikamatsu K; Sakakura K; Takahashi G; Okamoto A; Furuya N; Whiteside TL; DeLeo AB; Masuyama K
Cancer Immunol Immunother; 2009 Sep; 58(9):1441-8. PubMed ID: 19184003
[TBL] [Abstract][Full Text] [Related]
2. Toward the development of multi-epitope p53 cancer vaccines: an in vitro assessment of CD8(+) T cell responses to HLA class I-restricted wild-type sequence p53 peptides.
Sakakura K; Chikamatsu K; Furuya N; Appella E; Whiteside TL; Deleo AB
Clin Immunol; 2007 Oct; 125(1):43-51. PubMed ID: 17631051
[TBL] [Abstract][Full Text] [Related]
3. CD4+ T helper responses in squamous cell carcinoma of the head and neck.
Chikamatsu K; Sakakura K; Yamamoto T; Furuya N; Whiteside TL; Masuyama K
Oral Oncol; 2008 Sep; 44(9):870-7. PubMed ID: 18221909
[TBL] [Abstract][Full Text] [Related]
4. Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer.
Qian F; Gnjatic S; Jäger E; Santiago D; Jungbluth A; Grande C; Schneider S; Keitz B; Driscoll D; Ritter G; Lele S; Sood A; Old LJ; Odunsi K
Cancer Immun; 2004 Nov; 4():12. PubMed ID: 15521719
[TBL] [Abstract][Full Text] [Related]
5. Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants.
Hoffmann TK; Nakano K; Elder EM; Dworacki G; Finkelstein SD; Appella E; Whiteside TL; DeLeo AB
J Immunol; 2000 Nov; 165(10):5938-44. PubMed ID: 11067956
[TBL] [Abstract][Full Text] [Related]
6. Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell.
Tanaka M; Butler MO; Ansén S; Imataki O; Berezovskaya A; Nadler LM; Hirano N
Clin Cancer Res; 2011 Aug; 17(16):5392-401. PubMed ID: 21705450
[TBL] [Abstract][Full Text] [Related]
7. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.
Mandic M; Castelli F; Janjic B; Almunia C; Andrade P; Gillet D; Brusic V; Kirkwood JM; Maillere B; Zarour HM
J Immunol; 2005 Feb; 174(3):1751-9. PubMed ID: 15661941
[TBL] [Abstract][Full Text] [Related]
8. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer.
Hoffmann TK; Donnenberg AD; Finkelstein SD; Donnenberg VS; Friebe-Hoffmann U; Myers EN; Appella E; DeLeo AB; Whiteside TL
Cancer Res; 2002 Jun; 62(12):3521-9. PubMed ID: 12067999
[TBL] [Abstract][Full Text] [Related]
9. Relationships between regulatory T cells and CD8+ effector populations in patients with squamous cell carcinoma of the head and neck.
Chikamatsu K; Sakakura K; Whiteside TL; Furuya N
Head Neck; 2007 Feb; 29(2):120-7. PubMed ID: 17103408
[TBL] [Abstract][Full Text] [Related]
10. Alteration of cellular and humoral immunity by mutant p53 protein and processed mutant peptide in head and neck cancer.
Couch ME; Ferris RL; Brennan JA; Koch WM; Jaffee EM; Leibowitz MS; Nepom GT; Erlich HA; Sidransky D
Clin Cancer Res; 2007 Dec; 13(23):7199-206. PubMed ID: 18056201
[TBL] [Abstract][Full Text] [Related]
11. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck.
Eura M; Chikamatsu K; Katsura F; Obata A; Sobao Y; Takiguchi M; Song Y; Appella E; Whiteside TL; DeLeo AB
Clin Cancer Res; 2000 Mar; 6(3):979-86. PubMed ID: 10741724
[TBL] [Abstract][Full Text] [Related]
12. p53 as an immunotherapeutic target in head and neck cancer.
Hoffmann TK; Bier H; Donnenberg AD; Whiteside TL; De Leo AB
Adv Otorhinolaryngol; 2005; 62():151-60. PubMed ID: 15608425
[TBL] [Abstract][Full Text] [Related]
13. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins.
Asai T; Storkus WJ; Mueller-Berghaus J; Knapp W; DeLeo AB; Chikamatsu K; Whiteside TL
Cancer Immun; 2002 Apr; 2():3. PubMed ID: 12747748
[TBL] [Abstract][Full Text] [Related]
14. Identification of multiple HLA-DR-restricted epitopes of the tumor-associated antigen CAMEL by CD4+ Th1/Th2 lymphocytes.
Slager EH; van der Minne CE; Krüse M; Krueger DD; Griffioen M; Osanto S
J Immunol; 2004 Apr; 172(8):5095-102. PubMed ID: 15067093
[TBL] [Abstract][Full Text] [Related]
15. Disease-stage variance in functional CD4(+) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes.
Warrino DE; Olson WC; Knapp WT; Scarrow MI; D'Ambrosio-Brennan LJ; Guido RS; Edwards RP; Kast WM; Storkus WJ
Clin Cancer Res; 2004 May; 10(10):3301-8. PubMed ID: 15161683
[TBL] [Abstract][Full Text] [Related]
16. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma.
Tatsumi T; Kierstead LS; Ranieri E; Gesualdo L; Schena FP; Finke JH; Bukowski RM; Mueller-Berghaus J; Kirkwood JM; Kwok WW; Storkus WJ
J Exp Med; 2002 Sep; 196(5):619-28. PubMed ID: 12208877
[TBL] [Abstract][Full Text] [Related]
17. Identification of CDCA1-derived long peptides bearing both CD4+ and CD8+ T-cell epitopes: CDCA1-specific CD4+ T-cell immunity in cancer patients.
Tomita Y; Yuno A; Tsukamoto H; Senju S; Yoshimura S; Osawa R; Kuroda Y; Hirayama M; Irie A; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
Int J Cancer; 2014 Jan; 134(2):352-66. PubMed ID: 24734272
[TBL] [Abstract][Full Text] [Related]
18. MAGE-A3 and MAGE-A4 specific CD4(+) T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes.
Cesson V; Rivals JP; Escher A; Piotet E; Thielemans K; Posevitz V; Dojcinovic D; Monnier P; Speiser D; Bron L; Romero P
Cancer Immunol Immunother; 2011 Jan; 60(1):23-35. PubMed ID: 20857101
[TBL] [Abstract][Full Text] [Related]
19. The wild-type sequence (wt) p53(25-35) peptide induces HLA-DR7 and HLA-DR11-restricted CD4+ Th cells capable of enhancing the ex vivo expansion and function of anti-wt p53(264-272) peptide CD8+ T cells.
Ito D; Albers A; Zhao YX; Visus C; Appella E; Whiteside TL; DeLeo AB
J Immunol; 2006 Nov; 177(10):6795-803. PubMed ID: 17082593
[TBL] [Abstract][Full Text] [Related]
20. Maturation of circulating dendritic cells and imbalance of T-cell subsets in patients with squamous cell carcinoma of the head and neck.
Sakakura K; Chikamatsu K; Takahashi K; Whiteside TL; Furuya N
Cancer Immunol Immunother; 2006 Feb; 55(2):151-9. PubMed ID: 15889251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]